A proper GLP-1 assessment may include weight history, prior treatment, medications, eating behavior, gastrointestinal symptoms, pregnancy plans, gallbladder or pancreatic history, kidney function, metabolic risk, contraindications, and a plan for side effects and follow-up
Human evidence - Phase 3 TRIUMPH-1 (Eli Lilly, May 21, 2026) 2,339 adults with obesity or overweight without diabetes
Prior weight loss attempt documentation
When claims are drawn from these sources, they are attributed to "Omzo's published materials" or "per Omzo's Terms." FDA.gov primary sources: The FDA's public page on unapproved GLP-1 drugs, the April 30, 2026 FDA press release on the 503B Bulks List proposal, and the Federal Register notice 91 Fed